| Literature DB >> 26387754 |
Lena Ho1, Shawn Y X Tan2, Sheena Wee3, Yixuan Wu2, Sam J C Tan2, Navin B Ramakrishna2, Serene C Chng2, Srikanth Nama2, Iwona Szczerbinska, Iwona Sczerbinska4, Yun-Shen Chan4, Stuart Avery2, Norihiro Tsuneyoshi2, Huck Hui Ng4, Jayantha Gunaratne3, N Ray Dunn2, Bruno Reversade5.
Abstract
ELABELA (ELA) is a peptide hormone required for heart development that signals via the Apelin Receptor (APLNR, APJ). ELA is also abundantly secreted by human embryonic stem cells (hESCs), which do not express APLNR. Here we show that ELA signals in a paracrine fashion in hESCs to maintain self-renewal. ELA inhibition by CRISPR/Cas9-mediated deletion, shRNA, or neutralizing antibodies causes reduced hESC growth, cell death, and loss of pluripotency. Global phosphoproteomic and transcriptomic analyses of ELA-pulsed hESCs show that it activates PI3K/AKT/mTORC1 signaling required for cell survival. ELA promotes hESC cell-cycle progression and protein translation and blocks stress-induced apoptosis. INSULIN and ELA have partially overlapping functions in hESC medium, but only ELA can potentiate the TGFβ pathway to prime hESCs toward the endoderm lineage. We propose that ELA, acting through an alternate cell-surface receptor, is an endogenous secreted growth factor in human embryos and hESCs that promotes growth and pluripotency.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26387754 DOI: 10.1016/j.stem.2015.08.010
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633